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Abstract Stromal cell-derived factor 1K (SDF-1K) is a
chemokine that has been shown to prevent infection of T-tropic
HIV strains and is a possible substrate of CD26/dipeptidyl
peptidase IV (DPPIV). In this study, we show that SDF-1K was
cleaved at the N-terminal region by CD26/DPPIV and as a
result the inhibitory activity of SDF-1K against HIV infection
disappeared. Moreover, the chemotactic activity of SDF-1K also
disappeared specifically by DPPIV activity of recombinant
soluble CD26. These results suggested that dissemination of T-
tropic HIV strains in vivo may be facilitated by CD26/DPPIV
via inactivation of functional SDF-1K.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
CD26 is a widely distributed 110-kDa cell surface glycopro-
tein with known dipeptidyl peptidase IV (DPPIV; EC
3.4.14.5) activity in its extracellular domain. This ectoenzyme
is capable of cleaving N-terminal dipeptides from polypep-
tides with either Pro or Ala residue in the penultimate posi-
tion [1^4]. On human T cells CD26 expression appears late in
thymic di¡erentiation and is preferentially restricted to the
CD4 helper memory cell population [2]. Previously we
have shown that CD26 can deliver a potent co-stimulatory
T cell activation signal and DPPIV activity is essential for
CD26-mediated T cell co-stimulation [5,6]. From its cDNA
sequence, CD26 is predicted to be a type II integral membrane
protein with a large extracellular domain, transmembrane seg-
ment, and a cytoplasmic tail of six amino acids (aa), suggest-
ing that in addition to DPPIV activity, other signal-inducing
molecules may be associated with CD26 [7]. Previously, we
have demonstrated that CD26 is physically associated, pre-
sumably in its extracellular domain, with CD45, a mem-
brane-linked protein-tyrosine phosphatase [8]. More recent
studies from our laboratory have shown that CD26 is identi-
cal to the adenosine deaminase (ADA)-binding protein [9^11].
CD45 and ADA are both thought to be important in regu-
lation of T cell activation and signal transduction.
Chemokines play an important role in in£ammation by
attracting leukocytes [12]. Many kinds of chemokines and
their receptors have been identi¢ed in the past few years,
and importantly, it has been demonstrated that two of those
chemokine receptors, namely CXCR4 and CCR5, function as
coreceptors for infection of T-tropic (infects T cell lines) and
M-tropic (infects macrophage and activated T cells) strains of
HIV, respectively [13^19]. Subsequently, chemokines SDF-1
(stromal cell derived factor-1), a CXCR4 ligand, and
RANTES (regulated on activation, normal T cell expressed
and secreted) and MIP (macrophage in£ammatory proteins)
1K and 1L, CCR5 ligands, were reported to block the cell
entry of T-tropic and M-tropic HIV, respectively [20^22]. It
is remarkable that several chemokines, including SDF-1K,
RANTES and MIP-1L, have the conserved aa sequence for
the substrate of DPPIV at the N-terminus, and T cells capable
of transendothelial migration are those which express the
highest levels of CD26 [23]. These observations have led us
to the hypothesis that behavior of the chemokine might be
modi¢ed by CD26/DPPIV. In this regard, it was shown that
the receptor speci¢city and function of RANTES is regulated
by CD26/DPPIV-mediated cleavage [24]. Recently, we re-
ported that SDF-1 secreted from cells expressing CD26 mol-
ecules lost anti-HIV and chemotactic activity mediated by
SDF-1 [25]. Therefore, experiments that more directly study
the interaction between SDF-1 and CD26/DPPIV and its
functional consequences were required.
In this study we examined whether SDF-1 is a substrate for
CD26/DPPIV and the interaction of SDF-1 with CD26/
DPPIV a¡ects anti-HIV and chemotactic activity. We devel-
oped CD26-transfectants from Jurkat T cell line that origi-
nally does not express CD26 and recombinant soluble CD26s
(DPPIV and DPPIV3) [26,27]. Here we directly demonstrate
that CD26/DPPIV cleaves SDF-1K as a substrate and the
cleavage of SDF-1K by CD26/DPPIV results in a loss of in-
hibition of HIV cell entry with SDF-1K. Moreover, we show
that CD26/DPPIV causes a loss of chemotactic activity of
SDF-1K. These results indicate that sensitivity against HIV
infection and migratory degree of T lymphocytes in in£am-
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mation would be modulated by CD26/DPPIV via SDF-1K in
vivo.
2. Materials and methods
2.1. Cell cultures
Murine ¢broblast L cells were grown in minimum essential medium
(MEM; Gibco-BRL, Gaithersburg, MD, USA) supplemented with
10% FCS (MEM/FCS). Jurkat T cell line was grown in RPMI 1640
(Gibco-BRL) supplemented with 10% FCS, and the CD26-transfec-
tants (DPPIV and DPPIV3) [27] were maintained in RPMI 1640
containing 10% FCS and 200 Wg/ml geneticin (Gibco-BRL). Expres-
sion of CD4 and CXCR4 molecules on s 95% of Jurkat cells and the
transfectants were con¢rmed by FACSCalibur (Becton Dickinson,
San Jose, CA, USA) analysis with monoclonal antibodies anti-CD4
(19thy) [27] and anti-CXCR4 (12G5; RpD Systems, Minneapolis,
MN, USA), respectively. CD26 expression was also analyzed with
monoclonal antibody 1F7 [2,27], and positive rates of parent Jurkat
cells and its transfectants were 0.7% and 99%, respectively.
2.2. Generation of recombinant SDF-1 peptides
A NotI-fragment containing coding sequence of SDF-1K was sub-
cloned into the NotI-site in pBluescript II SK(+) (Stratagene, La Jolla,
CA, USA) and resulted in pBS-SDF. To obtain recombinant plasmids
for expression, ¢ve kinds of oligonucleotides were used for PCR am-
pli¢cation by Ex-Taq DNA polymerase (Takara, Japan): 5P-ATT-





GCTACCGATGCCCCT-3P (Ex-S2). A 0.6-kb DNA fragment ampli-
¢ed from pET-30a(+) (Novagen, Madison, WI, USA) using Ex-N and
Ex-EK as primers, and a 0.5-kb DNA fragment ampli¢ed from pBS-
SDF using Ex-S1 and Ex-C2 as primers, were puri¢ed from PCR
products and mixed, and PCR was performed again using primers
Ex-N and Ex-C2. The resulting 1.1-kb DNA fragment was digested
with SphI and XhoI, ligated with SphI-XhoI digested pET-30a(+),
yielding a SDF-1 encoding plasmid named pET-SDF1. Similarly,
pET-SDF2 was constructed using Ex-S2 instead of Ex-S1 as a primer
to produce the polypeptide in which 2 N-terminal amino acids (Lys-
Pro) were deleted (2 aa-truncated SDF-1K). The nucleotide sequences
of pET-SDF1 and pET-SDF2 were con¢rmed by analysis with ABI
373S sequencing system (Perkin Elmer, Japan).
Native and 2 aa-truncated SDF-1K were produced as SWtag fusion
protein by pET expression system and puri¢ed by SWTag fusion puri-
¢cation system (Novagen) according to the manufacturer’s manual.
Alternatively, Escherichia coli BL21 (DE3) harboring either pET-SDF
or pET-SDF2 were solubilized with ¢nal concentration of 4 M urea
and recombinant SDF-1K polypeptides were allowed to bind to S-
protein agarose under 2 M urea condition. SWTag fusion proteins
bound to S-protein agarose were washed and treated with recombi-
nant enterokinase (Novagen) at room temperature. After 16 h incu-
bation enterokinase was removed by rEK capture agarose (Novagen)
and recombinant SDF-1K peptides were eluted. Puri¢ed polypeptides
were dialyzed with PBS and concentrated by Centricon-3 (Amicon,
Beverly, MA, USA).
2.3. Cleavage of SDF-1K by sCD26
Recombinant soluble CD26 (sCD26) with DPPIV activity and mu-
tant soluble CD26 (mCD26) which lacks DPPIV activity were pre-
pared as described previously [26]. A speci¢c DPPIV activitiy of
sCD26 was 0.9 nmol p-nitroaniline released/min/Wg whereas the activ-
ity of mCD26 was undetectable as determined by colorimetric assay
using Gly-Pro-p-nitroaniline p-tosylate as a substrate. Five Wg of na-
tive SDF-1K was mixed with 5 Wg of sCD26 or mCD26 in 20 Wl of
PBS, and incubated at 37‡C for 1 h. The reacted SDF-1K was sepa-
rated with 20% SDS-polyacrylamide gel and electrotransferred to
PVDF membrane for peptide sequencing. The N-terminal aa sequence
was determined using HP G1005A protein sequencing system (Hew-
lett Packard, Palo Alto, CA, USA).
2.4. Cell-cell fusion assay
To clarify whether cell entry of HIV is achieved, we employed cell-
cell fusion assay based on T7 RNA polymerase-dependent L-galacto-
sidase expression [13]. As e¡ector cells, mouse L cells were transfected
with pET-30b(+) (Novagen) containing L-galactosidase gene using
Lipofectamine (Gibco-BRL), followed by infection with recombinant
vaccinia virus containing the envelope genes of HIV-1NL43 (Vac-
EnvNL43). As responder cells, L cells were infected with recombinant
vaccinia viruses containing human CD4 gene (Vac-CD4), bacterio-
phage T7 RNA polymerase gene (Vac-T7), and recombinant Sendai
virus containing human CXCR4 gene (Sen-CXCR4) [28], while Jurkat
T cells were infected with Vac-T7 only. Cells were infected at 10
multiplicity of infection for each recombinant virus. Cells were har-
vested after 24 h incubation at 37‡C, washed with MEM/FCS twice,
and resuspended with MEM/FCS. Responder cells were mixed with
MEM/FCS containing recombinant SDF-1K and/or recombinant
soluble CD26, and then e¡ector cells were added. After 3 h incubation
at 37‡C, cells were lysed with 0.25% ¢nal concentration of Nonidet P-
40. Fifty Wl of cell lysate was added to 50 Wl of substrate solution
consisting of 120 mM Na2HPO4, 80 mM NaH2PO4, 20 mM KCl,
2 mM MgSO4, 10 mM 2-mercaptoethanol and 16 mM chlorophenol
red-L-D-galactopyranoside, and the L-galactosidase activity was deter-
mined by change of A595.
2.5. Migration assay
Isolation of human peripheral blood mononuclear cells and E ro-
sette-positive (E) cells from healthy volunteers was described previ-
ously [2]. For further elimination of monocytes, E cells were cultured
in plastic dishes and non-adherent cells were used as a source of T
cells throughout this experiment. Native or 2 aa-truncated SDF-1K
with/without sCD26 or mCD26 were diluted in assay medium con-
sisting of RPMI 1640 and 0.3% BSA, and incubated at 37‡C for 1 h,
followed by addition to culture plates in a ¢nal volume of 600 Wl.
Culture inserts (Transwell 3421, 5 Wm pore size; Coster, Cambridge,
MA, USA) were wetted with assay medium at 37‡C for 1 h prior to
use and transferred to culture plates, and 5U105 T cells resuspended
in assay medium were added to each insert in a volume of 100 Wl.
Migration assay was performed by incubation at 37‡C for 3.5 h. Cells
migrated to the bottom chamber were harvested and counted using a
Coulter EPICS XL £ow cytometer for a set time period of 30 s [23].
3. Results and discussion
Although we showed indirectly that SDF-1 appears to be a
substrate of CD26/DPPIV [25], there still is a possibility that
other cellular components may be involved in the cleavage of
SDF-1. Therefore, we ¢rst determined whether CD26/DPPIV
cleaves SDF-1K without other factors in vitro. For this pur-
pose, we have developed recombinant soluble CD26s
(DPPIV and DPPIV3) secreted from transfected CHO cells
[24]. As a result, N-terminal sequencing of SDF-1K after in-
cubation with sCD26 revealed that SDF-1K was cleaved in
front of the third Val residue (Val-Ser-Leu-Ser-Tyr was deter-
mined as the N-terminal aa sequence), whereas the untrun-
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Table 1
E¡ect of sCD26 DPPIV activity on chemotaxis with SDF-1K
Assay medium containing: None sCD26 mCD26
None 827 þ 127 675 þ 36 668 þ 130
Native SDF-1K 1309 þ 251 706 þ 49 1605 þ 301
Values indicate means of transmigrated T cell count and standard errors obtained from triplicate experiments. Final concentration of 50 ng/ml for
SDF-K and 660 ng/ml for sCD26 or mCD26 were added (1:1 of molar ratio).
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cated N-terminal aa sequence (Lys-Pro-Val-Ser-Leu) of SDF-
1K was detected when SDF-1K was incubated with mCD26, a
DPPIV-defective form of sCD26 (data not shown). This result
clearly indicated that SDF-1K is cleaved as a physiological
substrate of CD26/DPPIV.
As the cleavage of SDF-1K by CD26/DPPIV was demon-
strated, we attempted to determine whether the infectivity of
T-tropic HIV-1NL43 was a¡ected by the interaction between
CD26 and SDF-1K by cell-cell fusion assay system using a
Jurkat T cell line. This assay system made the experiment
easy to investigate cell-entry step in HIV infection speci¢cally
because the color development dependent on L-galactosidase
activity was observed only if cell-cell fusion between e¡ector
cells having the L-galactosidase gene under control of T7 pro-
moter and responder cells having T7 RNA polymerase oc-
curred. As shown in Fig. 1A, we con¢rmed that the infection
by HIV was strongly inhibited in the presence of native SDF-
1K (14.1% level of infection compared with the absense of
either SDF-1K or recombinant soluble CD26). More signi¢-
cantly, the inhibitory activity of native SDF-1K was abolished
by addition of sCD26 (57.7% level of infection) whereas the
inhibitory activity still remained (26.2% level of infection)
when mCD26 was added (Fig. 1A). In marked contrast, the
infection was not inhibited by addition of 2 aa-truncated
SDF-1K, or addition of either sCD26 or mCD26 alone (Fig.
1A). In this regard, the importance of N-terminus of SDF-1K
has been shown to block infection by T-tropic HIV strains,
and also N-terminal truncated SDF-1K failed to block the
infection [21,22,29]. These results suggested that native SDF-
1K appears to lose the inhibitory activity by CD26-mediated
cleavage. In Fig. 1A we can see a slight disappearance of the
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Fig. 2. E¡ect of DPPIV activity of sCD26 on inhibition of CXCR4-
mediated infection of HIV-1NL43 by SDF-1K, monitored with L-ga-
lactosidase activity dependent on cell-cell fusion. 1U105 cells of
murine ¢broblast L transfected with pET-30b(+) containing L-galac-
tosidase gene, expressing human CD4 and human CXCR4, were in-
cubated with 1U105 cells of murine ¢broblast L expressing T7
RNA polymerase and the envelope glycoproteins of HIV-1NL43. Na-
tive or 2 aa-truncated SDF-1K was added at a ¢nal concentration
of 3 Wg/ml. Results from independent triplicate experiments are indi-
cated as level of infection calculated from the L-galactosidase activ-
ity observed in the absence of SDF-1K and recombinant soluble
CD26 (100% of infection). Determined L-galactosidase activity in
mouse L cells without SDF-1K and recombinant soluble CD26 was
0.818 A595 increase/h. Addition of recombinant soluble CD26 is in-
dicated as a ¢nal concentration with abbreviations: 3, not added;
1s, 1 Wg/ml of sCD26; 10s, 10 Wg/ml of sCD26; 1m, 1 Wg/ml of
mCD26; 10m, 10 Wg/ml of mCD26. Asterisk and double asterisks
mean P6 0.001 and P6 0.005 as compared with the result in the
absence of SDF-1K and recombinant soluble CD26 (100% of infec-
tion) by Student’s t-test, respectively.
Fig. 1. Inhibition of CXCR4-mediated infection of HIV-1NL43 by
native and 2 aa-truncated SDF-1K, monitored with L-galactosidase
activity dependent on cell-cell fusion. 3U105 cells of parent Jurkat
T cell line (A), wild-type CD26 (DPPIV) transfectant (B) and mu-
tant CD26 (DPPIV3) transfectant (C) were infected with Vac-T7,
and then incubated with 1U105 cells of murine ¢broblast L contain-
ing T7 promoter-dependent L-galactosidase gene and expressing the
envelope glycoproteins of HIV-1NL43. Native or 2 aa-truncated
SDF-1K was added with a ¢nal concentration of 3 Wg/ml, and
sCD26 or mCD26 was added with a ¢nal concentration of 1 Wg/ml.
Results from independent triplicate experiments are indicated as lev-
el of infection calculated from the L-galactosidase activity observed
in the absence of SDF-1K and recombinant soluble CD26 (100% of
infection). Determined L-galactosidase activities in parent (A), CD26
(DPPIV) transfectant (B) and CD26 (DPPIV3) transfectant (C)
without SDF-1K and recombinant soluble CD26 were 0.149, 0.08
and 0.147 A595 increase/h, respectively. Addition of recombinant
SDF-1K and recombinant soluble CD26 is indicated in the bottom
line with abbreviations: 3, not added; N, native SDF-1K ; T, 2 aa-
truncated SDF-1K ; S, sCD26; M, mCD26. Asterisk and double as-
terisks mean P6 0.001 and P6 0.005 as compared with the result in
the absence of SDF-1K and recombinant soluble CD26 (100% of in-
fection) by Student’s t-test, respectively.
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inhibitory activity in native SDF-1K incubated with mCD26.
It should be noted that native SDF-1K incubated with mCD26
was also cleaved when an excess amount of mCD26 (50 Wg per
5 Wg of SDF-1K) was added and in vitro cleavage was per-
formed overnight, although the DPPIV activity of mCD26
was undetectable with colorimetric assay. In rat DPPIV, Oga-
ta et al. [30] described that it is essential to preserve not only
the catalytic site of Ser631 (corresponding to Ser630 of human
DPPIV) but also Gly629, Tyr632 and Gly633 (Gly628, Tyr631 and
Gly632 in human DPPIV) for proteolytic activity. Since the
recombinant soluble CD26 lacking DPPIV activity was cre-
ated by a single substitution of Ala for the putative catalytic
Ser residue at position 630 [27], this mutation may not be
su⁄cient to lose the DPPIV activity completely.
Next we determined whether the cell surface CD26 mole-
cule interacts with SDF-1K and this interaction a¡ects the
infectivity of HIV. For this purpose, we utilized wild-type
CD26 (DPPIV) and mutant CD26 (DPPIV3) transfectants
of Jurkat cell line as we previously established [27]. As shown
in Fig. 1B, when the transfectants expressing wild-type CD26
(DPPIV) were used, native SDF-1K did not inhibit HIV in-
fection (82.5% level of infection). Moreover, the inhibitory
activity of HIV infection by SDF-1K was not a¡ected by
the presence of sCD26 or mCD26. However, in mutant
CD26 (DPPIV3) transfectant, SDF-1K inhibited the HIV in-
fection (26.5% level of infection; Fig. 1C). In these cells, sim-
ilar to the results observed in parent Jurkat cells, the inhib-
itory activity of SDF-1K disappeared in the presence of
sCD26 (95.2% level of infection), and the modest inhibitory
activity of HIV infection by SDF-1K was observed in the
presence of mCD26 (61.2% level of infection; Fig. 1C). The
addition of 2 aa-truncated SDF-1K consistently did not inhibit
the HIV infection in either of the Jurkat CD26-transfectants
regardless of the presense of sCD26 or mCD26 (80^170% level
of infection; Fig. 1B,C). These results indicate that the pres-
ence of CD26/DPPIV on cell surface causes loss of inhibitory
activity of SDF-1K against HIV. Interestingly, the transfectant
expressing wild-type CD26 (DPPIV) was relatively resistant
against HIV infection in the absence of SDF-1K and sCD26,
as compared with the parent Jurkat T cell line (50% level of
infection compared to parent cells) which we also observed
previously [27]. It is conceivable that an interaction of CD26
with other cell surface molecules or other factors may a¡ect
the infectivity of HIV. Further studies are now in progress to
de¢ne why cells expressing CD26 are resistant to HIV infec-
tion.
To determine more speci¢cally the in£uence of the interac-
tion between SDF-1K and sCD26 upon HIV infection, we
next performed a cell-cell fusion assay using murine ¢broblast
L cells expressing human CD4 and human CXCR4 as the
responder cells instead of the Jurkat T cell line. As shown
in Fig. 2, it was con¢rmed that native SDF-1K strongly in-
hibited HIV infection (26.3% level of infection), the inhibitory
activity disappeared in the presence of sCD26 (113% level of
infection), and the 2 aa-truncated form of SDF-1K was unable
to inhibit the HIV infection (95.7% level of infection). Addi-
tion of a 10-fold amount of sCD26 alone (¢nal concentration
of 10 Wg/ml) did not a¡ect the HIV infection, indicating that
soluble CD26 might not interact with HIV envelope (Fig. 2).
These ¢ndings further emphasize that the interaction between
SDF-1K and CD26, whether it was presented on cell surface
or as a soluble form, occurred through proteolytic cleavage
since the anti-HIV activity of native SDF-1K was lost only
when the DPPIV activity of CD26 was present in either mouse
L cells or the Jurkat T cell line.
Since chemokines play a critical role in T cell migration and
in vivo migrating T cells expressed a high level of CD26, we
next investigated the e¡ect of the interaction between sCD26
and SDF-1K on T cell migration. As shown in Table 1, native
SDF-1K had a chemotactic activity for T cells in agreement
with previous studies [21,22,29]. It is noteworthy that the
chemotactic activity of SDF-1K was abolished by addition
of sCD26 whereas the chemotactic activity of SDF-1K was
not a¡ected in the presence of mCD26 (Table 1). These results
indicated that the N-terminal cleavage of SDF-1K by sCD26
caused disappearance of the function not only to block HIV
infection but also to induce T cell chemotaxis. In the light of
previous observations that the N-terminal 2 aa residues of
SDF-1K are essential for cell migration and that receptor sig-
nalling of 2 aa-truncated SDF-1K is not detected although the
binding activity was retained [29], our ¢ndings indicate that
CD26/DPPIV physiologically modulates chemotactic activity
of SDF-1K via cleavage of the N-terminus essential for induc-
tion of chemotaxis.
The cleavage of SDF-1K by CD26 found in this study is
easily considered to occur in vivo. T-tropic HIVs are known
to be rampant in HIV-infected individuals at a late stage of
the disease. Considering the fact that soluble CD26 with
DPPIV activity is present in human plasma [31] and that
CD26 molecules play an important role in memory T cell
activation and function [5,6,26], there is a possibility that
CD26 counteracts the protective measure in human body
against T-tropic HIV, including SDF-1K, and would even
facilitate HIV dissemination. However, for M-tropic HIV
which is generally found in an early stage of the disease,
RANTES was recently reported to retain or rather enhance
its anti-HIV activity via an interaction with the receptor
CCR5 after cleavage by CD26/DPPIV, though the cleaved
RANTES had less a⁄nity with another receptor, CCR1
[24,32]. So far it has been described that several chemokines
other than SDF-1 and RANTES contain the conserved
cleavage site of CD26/DPPIV. Therefore, it is expected that
an in vivo general modulation of various chemokines is in-
duced by cell surface CD26 as well as soluble form CD26 in
plasma.
In summary, we showed that a chemokine, SDF-1K, is a
substrate for CD26/DPPIV, and interaction between both
membrane and soluble forms of CD26/DPPIV and SDF-1K
caused the disappearance of the inhibitory activity against
HIV infection and migratory activity for T cells. These results
indicated that CD26/DPPIV is a potent intrinsic modulatory
factor of protective as well as in£ammatory responses through
interaction with chemokines.
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